Mesa Laboratories (NASDAQ:MLAB) Issues Earnings Results, Misses Expectations By $2.14 EPS

Key Points

• Mesa Laboratories reported quarterly EPS of $0.49, missing the $2.63 consensus estimate by $2.14. Revenue was $60.14 million, slightly below expectations of $60.87 million.
• The stock fell 1.0% to $101.62 following the results. Analysts maintain a “Reduce” consensus rating, with an average price target of $94.00.
• The company declared a quarterly dividend of $0.16 per share, equal to a $0.64 annualized payout and a 0.6% yield; the dividend is payable September 15 to shareholders of record on August 31.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) posted its quarterly earnings results on Monday. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.63 by ($2.14), FiscalAI reports. The company had revenue of $60.14 million during the quarter, compared to the consensus estimate of $60.87 million. Mesa Laboratories had a net margin of 2.69% and a return on equity of 20.96%.

Mesa Laboratories Stock Down 1.0%

Mesa Laboratories stock traded down $1.03 during mid-day trading on Monday, hitting $101.62. The company's stock had a trading volume of 103,018 shares, compared to its average volume of 145,376. The firm's 50 day moving average is $100.33 and its 200 day moving average is $95.20. The company has a market cap of $569.07 million, a PE ratio of 84.68 and a beta of 0.92. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.72 and a quick ratio of 1.29. Mesa Laboratories has a 52-week low of $58.83 and a 52-week high of $113.99.

Mesa Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Monday, August 31st will be given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Monday, August 31st. Mesa Laboratories's payout ratio is presently 53.33%.

Analysts Set New Price Targets

Separately, Weiss Ratings cut Mesa Laboratories from a "sell (d+)" rating to a "sell (d)" rating in a research note on Wednesday, June 3rd. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Mesa Laboratories currently has an average rating of "Reduce" and a consensus target price of $94.00.

Insider Buying and Selling at Mesa Laboratories

In related news, CFO John Sakys sold 2,827 shares of the business's stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $89.50, for a total transaction of $253,016.50. Following the transaction, the chief financial officer directly owned 19,785 shares of the company's stock, valued at approximately $1,770,757.50. The trade was a 12.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Brian David Archbold sold 2,516 shares of the company's stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $89.50, for a total transaction of $225,182.00. Following the completion of the transaction, the senior vice president owned 6,377 shares in the company, valued at approximately $570,741.50. This represents a 28.29% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 8,277 shares of company stock valued at $770,122 in the last 90 days. 2.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Mesa Laboratories

Several institutional investors and hedge funds have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. boosted its position in Mesa Laboratories by 5,366.7% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier's stock valued at $26,000 after purchasing an additional 322 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Mesa Laboratories during the 4th quarter worth about $27,000. Kestra Advisory Services LLC acquired a new stake in shares of Mesa Laboratories during the 4th quarter valued at about $55,000. BNP Paribas Financial Markets grew its stake in shares of Mesa Laboratories by 115.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 786 shares of the medical instruments supplier's stock valued at $74,000 after buying an additional 421 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in Mesa Laboratories by 432.9% in the second quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier's stock worth $79,000 after buying an additional 684 shares during the last quarter. 90.60% of the stock is currently owned by hedge funds and other institutional investors.

About Mesa Laboratories

Mesa Laboratories, Inc NASDAQ: MLAB is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company's product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source